Regeneron sues Sandoz over Eylea biosimilar

Intellectual Property 2025-07-02 11:39 pm By Cindy Cameronne | Sydney

Please login to bookmark

US biotech company Regeneron Pharmaceuticals has sued Sandoz, claiming it is threatening to infringe the patent for its Eylea biologic, used to treat macular degeneration and diabetic macular oedema.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au